Thumbs down to NKTR-181, Lilly expands its insu...

Juvenescence closes a USD 100 Million Series B round Juvenescence, a life sciences company focused on treating ageing problems, has successfully raised USD 100 Million in a Series B round. The investors who took part in the funding were Grok Ventures, the investment company of Mike Cannon-Brookes (Atlassian co-...

Chronic Lower Back Pain (CLBP) market size in 7MM is expected to grow at a CAGR of 4.84% for the study period (2017-2028). The CLBP therapy market although, is entirely dependent on supportive therapies, but the drugs such as opioids and NSAIDs, have also been approved to ease the pain associated with CLBP. The pre...

Each year, approximately 3.6 million people in the United States complain of Lower back pain (LBP). Among all types of chronic pain, back pain has often been suggested to be the most frequent type and is considered the second most common neurologic disease and most physician visits can be attributed to it. The lowe...

Chronic Lower Back Pain Chronic lower back pain (CLBP) is defined as pain that persists for 12 weeks or longer, even after an initial injury or the underlying cause of acute low back pain has been treated. Low back pain is very common and at one point everyone may have faced this problem. According to DelveIn...

Pompe disease is an inherited rare disease, often fatal with a potential to damage heart, liver and skeletal muscles. Absence of an essential protein, Due to the mutation in a gene encoding GAA, there is an absence of a critical protein leading to a complex buildup of sugar, hence, damaging heart, liver and other o...

The global Pompe disease market will experience a boost during the study period of 2019-28. Pompe disease is a rare inheritable disorder with a combined Pompe disease prevalence of 1 in 40,000, affecting males and females equally. The Pompe disease therapeutic market revolves around pharmacological treatment (wh...